Study of Markers of Iron Metabolism and Their Relationship With Phosphocalcic and Hepatic Metabolism and Inflammation in Hemodialysis Patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05586867

Acronym

MARMEFE

Enrollment

200

Registered

2022-10-19

Start date

2021-12-01

Completion date

2031-12-01

Last updated

2022-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Calcium Phosphate Metabolism, Hemodialysis Complication, Hepatic Metabolic Disorders, Iron Metabolism Disorders

Brief summary

From a scientific point of view and for publication purposes, it therefore seems important to study the metabolism of iron and in particular to define its conditions of absorption, metabolism, elimination and storage in the body at course of advanced renal failure. The study will follow the evolution of hormones regulating iron metabolism and put into perspective their links with phosphocalcic and hepatic metabolisms as well as inflammation in hemodialysis patients. The main objective of this program is to study the evolution of hepcidin and erythroferrone levels in hemodialysis patients. These two biomarkers regulating iron metabolism are not performed routinely in dialysis centers and are not listed in the nomenclature.

Interventions

PROCEDUREBlood test

15 mL of blood to follow the evolution of hepcidin and erythroferrone levels

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult dialysis patient * Patient able to understand the information necessary for the study and having signed his written consent to participate * Affiliated patient or beneficiary of a social security scheme.

Exclusion criteria

* Medically unstable or frail patient * Patient with hemoglobin less than 7g/dl * Patient with HIV+ or AIDS, patient with replicating hepatitis B or C * Patient participating in another clinical study requiring an additional blood sample * Patient benefiting from legal protection measures (guardianship, guardianship, etc.) adult under guardianship, guardianship or other legal protection, deprived of freedom by judicial or administrative decision * Pregnant, breastfeeding or parturient woman

Design outcomes

Primary

Measure	Time frame	Description
concentration of the two main markers concerning iron metabolism: hepcidin (ng/ml) and erythroferone (ng/ml).	5 years	These will be dosed twice over a year of dialysis and for 5 years

Countries

France

Contacts

Primary ContactJean-François Oudet

jeanfrancois.oudet@free.fr0683346567

Backup ContactMarie-Hélène Barba

mh.barba@ecten.eu

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026